Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders

• Published in: British journal of clinical pharmacology Vol. 88; no. 8; pp. 3803 - 3812
• Main Authors: Yan, Li, Wang, Bing, She, Dewei, Mitchell, Ben, Criste, Ryan, Cimbora, Daniel, Katz, Eliezer, Rees, William A.
• Format: Journal Article
• Language: English
• Published: England 01.08.2022
• Subjects: B cell; CD19; exposure–response; inebilizumab; NMOSD; pharmacodynamics; population modelling; B cell; CD19; pharmacodynamics; population modelling; inebilizumab; NMOSD; exposure-response

Aims Neuromyelitis optica spectrum disorders (NMOSD) is an autoantibody‐mediated, B cell‐driven disease. Inebilizumab is a humanized, affinity‐optimized, afucosylated IgG1 κ monoclonal antibody that binds to the B‐cell specific surface antigen CD19, resulting in rapid, profound and sustained depleti...